Eagle Pharmaceuticals (EGRX) Competitors $1.96 +0.04 (+2.08%) As of 03:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock EGRX vs. GNLX, OPTN, ORMP, PLRX, XBIT, ALTS, MGNX, EXOZ, GALT, and ANIXShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Genelux (GNLX), OptiNose (OPTN), Oramed Pharmaceuticals (ORMP), Pliant Therapeutics (PLRX), XBiotech (XBIT), Janone (ALTS), MacroGenics (MGNX), Exozymes (EXOZ), Galectin Therapeutics (GALT), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Genelux OptiNose Oramed Pharmaceuticals Pliant Therapeutics XBiotech Janone MacroGenics Exozymes Galectin Therapeutics Anixa Biosciences Genelux (NASDAQ:GNLX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Do analysts rate GNLX or EGRX? Genelux currently has a consensus target price of $18.25, suggesting a potential upside of 514.48%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer GNLX or EGRX? Eagle Pharmaceuticals received 396 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 65.81% of users gave Eagle Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes16100.00% Underperform VotesNo VotesEagle PharmaceuticalsOutperform Votes41265.81% Underperform Votes21434.19% Do institutionals and insiders believe in GNLX or EGRX? 37.3% of Genelux shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, GNLX or EGRX? Genelux has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Which has better valuation and earnings, GNLX or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K12,846.74-$28.30M-$0.96-3.09Eagle Pharmaceuticals$257.55M0.10$35.64MN/AN/A Does the media favor GNLX or EGRX? In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Genelux. MarketBeat recorded 2 mentions for Eagle Pharmaceuticals and 1 mentions for Genelux. Genelux's average media sentiment score of 1.87 beat Eagle Pharmaceuticals' score of 0.00 indicating that Genelux is being referred to more favorably in the media. Company Overall Sentiment Genelux Very Positive Eagle Pharmaceuticals Neutral Is GNLX or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Eagle Pharmaceuticals N/A N/A N/A SummaryEagle Pharmaceuticals beats Genelux on 9 of the 16 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.46M$6.79B$5.50B$7.84BDividend YieldN/A3.11%5.11%4.23%P/E RatioN/A7.3322.4518.52Price / Sales0.10240.48399.68103.35Price / Cash0.4065.8538.1834.62Price / BookN/A6.396.744.25Net Income$35.64M$142.94M$3.22B$248.05M7 Day Performance18.79%4.49%4.25%5.04%1 Month Performance122.73%-1.59%-0.88%1.70%1 Year Performance-51.60%-2.55%16.63%4.21% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle PharmaceuticalsN/A$1.96+2.1%N/A-53.8%$25.46M$257.55M0.00100News CoverageGap DownGNLXGenelux1.9345 of 5 stars$2.70+2.7%$18.25+575.9%-14.7%$93.43M$8,000.00-2.8410Gap UpOPTNOptiNose3.3067 of 5 stars$9.16-0.1%$9.00-1.7%-27.6%$92.26M$78.23M-2.18190Short Interest ↓News CoveragePositive NewsORMPOramed Pharmaceuticals1.2611 of 5 stars$2.25+4.7%N/A-8.9%$91.91M$1.34M20.4510News CoveragePLRXPliant Therapeutics4.1826 of 5 stars$1.48+1.4%$13.31+799.5%-87.6%$90.85M$1.58M-0.4490Upcoming EarningsNews CoverageXBITXBiotech1.3057 of 5 stars$2.97+1.0%N/A-63.4%$90.55M$4.01M-2.75100Gap UpALTSJanoneN/A$5.56+8.0%N/AN/A$89.40M$12.53M0.00170Positive NewsGap UpMGNXMacroGenics4.0202 of 5 stars$1.39+10.3%$7.38+430.6%-88.7%$87.70M$148.34M-0.88430Positive NewsEXOZExozymesN/A$10.47-3.4%N/AN/A$87.61MN/A0.0029GALTGalectin Therapeutics1.0872 of 5 stars$1.31-5.1%$11.00+739.7%-61.7%$87.19MN/A-1.799ANIXAnixa Biosciences2.0684 of 5 stars$2.69-1.1%$9.00+234.6%-13.3%$86.61M$210,000.00-6.905 Related Companies and Tools Related Companies GNLX Alternatives OPTN Alternatives ORMP Alternatives PLRX Alternatives XBIT Alternatives ALTS Alternatives MGNX Alternatives EXOZ Alternatives GALT Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.